Recent research on the dynamic behavior of the carnitine carrier underscores the importance of pathway led by CAC and carnitine-dependent acyltransferases in cancer cell metabolism, suggesting that modulation of this system could become a novel strategy for cancer treatment, aiming at reprogramming metabolism in mitochondrial diseases and cancer, providing a multifaceted approach to treatment development. The gene discussed is SLC25A20; the disease is mitochondrial disease.